Indication
Treatment of schizophrenia, or of moderate to severe manic episodes in bipolar I disorder with sensor to measure medication adherence
Loading your page…
Loading your page…
Schizophrenia;Bipolar Disorder
Marketing Authorisation Holder: Otsuka Pharmaceutical Netherlands B.V.
INN: aripiprazole
AI Drug & Interaction Analysis
Free account required
Ask Osler about Abilify MyCite: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.